Physician profile
Mark Belsky
NPI 1548284474
$8,018.05
in general payments reported to CMS, 2019-2025
47 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $353 · 2021: $734 · 2022: $1,259 · 2023: $1,761 · 2024: $1,676 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,753.03 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $920.03 | 2019-2025 | |
| Lilly USA, LLC | $729.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $593.61 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $491.76 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.41 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $360.37 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lundbeck LLC | $304.39 | 2023-2025 | Rexulti |
| Amgen INC. | $299.54 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Exact Sciences Corporation | $299.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $219.21 | 2019-2023 | |
| Astellas Pharma US INC | $195.77 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $193.26 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $126.01 | 2019-2025 | Spravato |
| Abbott Laboratories | $117.85 | 2019-2025 | Freestyle Libre 3 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Belsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.